JDRF

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Retrieved on: 
Friday, March 29, 2024
Conference, Editas Medicine, Biotechnology, Exercise, Immunotherapy, Patient, Research, Investment, SABS, Therapy, JDRF, Safety, SAB, Type 1 diabetes, Cryptocurrency

We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.

Key Points: 
  • We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.
  • A replay of Mr. Reich’s presentation will be archived on the SAB Biotherapeutics website for up to one year.
  • SAB Biotherapeutics held cash and equivalents of $56.6 million at December 31, 2023, compared to $15.0 million at December 31, 2022.
  • SAB reported a net loss of $42.2 million and $18.7 million for the years ended December 31, 2023 and December 31, 2022 respectively.

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, JDRF, Kidney disease, Massachusetts General Hospital, Risk, Immunosuppression, Patient, Kidney transplantation, OLE, University, Tacrolimus, Glomerular filtration rate, Net, Investment, Society, Hospital, EGFR, Kidney, Safety, Pharmacokinetics, FACS, Annual general meeting, Pharmaceutical industry

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • In addition to our clinical development progress, tegoprubart was used for immunosuppression in historical kidney and heart pig-to-human xenotransplant procedures.
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man with end-stage kidney disease.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting held in Philadelphia, PA in November 2023.
  • General and administrative expenses were $12.7 million for the year ended December 31, 2023, compared to $12.7 million for the year ended December 31, 2022.

Manasquan Bank Appoints Andrew Drechsler to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Diabetes, Villanova University, Sanofi, Chair, Growth, WALL, Patient, Bank, JDRF

WALL TOWNSHIP, N.J., April 9, 2024 /PRNewswire/ -- Manasquan Bank is proud to announce the appointment of Andrew Drechsler to its Board of Directors, effective April 24, 2024.

Key Points: 
  • WALL TOWNSHIP, N.J., April 9, 2024 /PRNewswire/ -- Manasquan Bank is proud to announce the appointment of Andrew Drechsler to its Board of Directors, effective April 24, 2024.
  • Mr. Drechsler is an accomplished financial and operational executive with extensive experience in both public and private companies in the life science industry.
  • "Andy's exceptional financial acumen and experience in leading successful life science companies will undoubtedly bring invaluable insights and expertise to our Board," stated James S. Vaccaro, Chair, CEO and President of Manasquan Bank.
  • "I'm honored to join Manasquan Bank's Board of Directors and be a part of an organization that values community involvement as much as I do," said Mr. Drechsler.

Type 1 diabetes researchers from across Canada sign letter of support for diabetes research to be included in the upcoming federal budget

Retrieved on: 
Monday, March 25, 2024
B cell, Letter, Science, Federation, Diabetes, Immunosuppression, Patient, Research, Investment, JDRF, Safety, Federal, CIHR, Pharmaceutical industry

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Top researchers in the field of type 1 diabetes (T1D) signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal Budget 2024.

Key Points: 
  • TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Top researchers in the field of type 1 diabetes (T1D) signed an open letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal Budget 2024.
  • The letter details the importance of funding research in the field of islet replacement therapy, of which Canada is a global leader.
  • As Canadian researchers working in the field of islet replacement therapy for diabetes, we write this letter in support of renewed funding for the JDRF-CIHR Partnership to Defeat diabetes through Federal Budget 2024.
  • Type 1 diabetes (T1D) is an autoimmune condition resulting in absolute insulin deficiency, for which there is no available cure.

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
CGM, Administration, G42, IROS, Type 2 diabetes, Incidence, Insulin, Patient, Level 2, G&A, Doctor of Philosophy, MD, VTV, Clinical research associate, Research and development, Therapy, JDRF, PIPE, Safety, Saṃsāra, FDA, Pharmaceutical industry

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • In connection with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members.
  • HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
  • Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2023, was $20.3 million or $9.71 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $19.2 million or $9.98 per basic share.

Q2 Named a 2024 Top Workplaces USA Winner

Retrieved on: 
Wednesday, March 20, 2024
Technology, Finance, Fintech, Banking, Professional Services, Philanthropy, Software, DEI (Diversity, Equity and Inclusion), Other Philanthropy, Culture, Organization, The Trevor Project, Partnership, JDRF, Management

Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced it has received the 2024 Top Workplaces USA award presented by Energage .

Key Points: 
  • Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for financial services, today announced it has received the 2024 Top Workplaces USA award presented by Energage .
  • The Top Workplaces USA award, built on the program’s 17-year history surveying more than 27 million employees across 60 markets, selects winners based on employee feedback gathered through an employee engagement survey.
  • “At Q2, our mission is to build strong and diverse communities by strengthening their financial institutions,” said Matt Flake, chief executive officer, Q2.
  • In 2023, Q2 team members volunteered more than 10,000 hours of service to their communities and shared $1.3 million with philanthropic organizations.

Floyd's 99 Barbershop Announces Howard Picker as Vice President of Franchise Development

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Picker, Culture, JDRF, Growth, Entrepreneurship, Environment

GREENWOOD VILLAGE, Colo., April 4, 2024 /PRNewswire/ -- Floyd's 99 Barbershop (Floyd's), the full-service haircare franchise known for its expert services in an amplified environment, is proud to announce the hiring of Howard Picker to the position of Vice President of Franchise Development. Picker carries 30+ years of experience in the franchising space, and has previously worked in a similar capacity with various franchisors, including Huntington Learning Center, Mathnasium, and FranLift, to name a few.

Key Points: 
  • GREENWOOD VILLAGE, Colo., April 4, 2024 /PRNewswire/ -- Floyd's 99 Barbershop (Floyd's), the full-service haircare franchise known for its expert services in an amplified environment, is proud to announce the hiring of Howard Picker to the position of Vice President of Franchise Development.
  • "We're thrilled to welcome Howard to Floyd's as we strive to achieve continued growth of the brand," said Paul O'Brien, Co-Founder and Co-Owner of Floyd's.
  • "With Howard's extensive background in franchising, we're confident he will play a vital role in driving our franchise development initiatives forward and strengthening our position as a leader in the haircare industry."
  • Joining Floyd's brings Picker's career full circle, as he was a multi-unit franchise owner of a haircare brand in the early 2000s.

Virginia "Ginny" Coarsey Joins Gilbane Building Company's North Florida Team to Drive Business Development

Retrieved on: 
Tuesday, March 26, 2024
Organization, Construction, History, University, Business development, JDRF, Engineering, Gilbane Building Company, AEC, Construction management, General contractor, Management

JACKSONVILLE, Fla., March 26, 2024 /PRNewswire-PRWeb/ -- Gilbane Building Company, a leading global builder and top contractor in the Southeast, announced that Virginia "Ginny" Coarsey has joined the company to manage business development in North Florida. Based out of Gilbane's Jacksonville, FL office, Coarsey is stepping into the position of Business Development Manager with a wealth of experience and relationships throughout the Construction, Architecture, and Engineering industry. After earning her degree from the University of Florida in Gainesville, she has gained valuable expertise overseeing Actalent's Construction Management, Architecture, and Engineering specializations for Northeast Florida.

Key Points: 
  • JACKSONVILLE, Fla., March 26, 2024 /PRNewswire-PRWeb/ -- Gilbane Building Company, a leading global builder and top contractor in the Southeast, announced that Virginia "Ginny" Coarsey has joined the company to manage business development in North Florida.
  • Based out of Gilbane's Jacksonville , FL office, Coarsey is stepping into the position of Business Development Manager with a wealth of experience and relationships throughout the Construction, Architecture, and Engineering industry.
  • Ginny compliments our local, talented, and dynamic team with her drive for excellence and passion for serving as a client advocate.
  • "Ginny compliments our local, talented, and dynamic team with her drive for excellence and passion for serving as a client advocate.

JDRF Shines Light on Type 1 Diabetes During Autoimmune Awareness Month

Retrieved on: 
Tuesday, March 26, 2024
Community, Diagnosis, Research, Health, Vitiligo, Disease, Partnership, Insulin, Risk, T1D, Autoantibody, Pancreas, JDRF, Immune system, FDA, Clinical trial, Autoimmune disease, Pharmaceutical industry

NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all. T1D is one of nearly 100 autoimmune diseases that occur when the body's immune system mistakenly attacks another part of the body. While there are currently no cures for autoimmune diseases, screening options may be available, which can reduce the risk of life-threatening complications at diagnosis and provide people time to develop a plan in partnership with their healthcare team. JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.

Key Points: 
  • Screening for type 1 diabetes can reduce the risk of life-threatening complications at diagnosis.
  • NEW YORK, March 26, 2024 /PRNewswire/ -- In recognition of Autoimmune Awareness Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes all those who live with T1D, an autoimmune condition that causes the pancreas to make very little insulin or none at all.
  • JDRF continues advancing breakthroughs to find cures for T1D, including research that has the potential to impact other autoimmune diseases.
  • JDRF encourages those with T1D and other autoimmune diseases to share their stories and continue to build awareness of their conditions and opportunities for screening.

JDRF Proudly Announces the Appointment of New International Board of Directors Vice Chair

Retrieved on: 
Wednesday, March 13, 2024
Royal Bank of Canada, Partnership, Royal Bank, T1D, Research, Parent, McMaster University, JDRF, International Board, Management

NEW YORK and TORONTO, March 13, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced the appointment of Matt Varey as the new vice chair of the non-profit's International Board of Directors. Matt, of Oakville, Ontario, is the first Canadian and first person from outside of the United States to hold the vice chair position. He is a senior executive at Royal Bank of Canada, the country's largest financial institution, where he is responsible for more than 4,500 Canada-based employees who manage personal investments, mortgage financing, and group benefits totaling more than $100 billion annually.  

Key Points: 
  • "We are delighted that Matt is taking on the role of vice chair of JDRF's International Board of Directors.
  • In addition to his work on JDRF's International Board of Directors, Matt serves on the board of JDRF Canada.
  • "I have been a JDRF volunteer for more than 20 years and am honored to step into the role of vice chair of JDRF's International Board of Directors", said Matt Varey.
  • Varey will be joined in his term of board leadership by Lisa Fishbone Wallack , the newly appointed chair of JDRF's International Board of Directors.